For matters of the heart, you want to find that someone special. But for practical purposes, it might pay off to find something special to help you take care of your heart.
Later this year, generic drugmaker Watson Pharmaceuticals will begin offering an authorized generic version of Lipitor, Pfizer's (PFE) blockbuster drug that aims to lower cholesterol and reduce the risk of heart disease.
In fact, Watson expects only one other competitor will have the rights to sell generic Lipitor, but that competition will only last about six months. After that, Watson will be the exclusive provider of the generic version of the one of the world's most popular drugs.
Thanks to those rights, Watson forecasts solid earnings this year, and double-digit annual growth for the next couple of years. Based on that healthy outlook, analysts at Credit Suisse expect Watson's stock to improve almost 12% to $64 per share this year.
NEXT: Alpha Natural Resources
